Skip to main content
. 2024 Sep 19;13(9):513–524. doi: 10.1302/2046-3758.139.BJR-2024-0109

Fig. 5.

Fig. 5

Findings from surveys when respondents were asked about how acceptable they thought it was to test a new drug in a clinical study that seeks to prevent post-traumatic osteoarthritis (PTOA) in people with different risks of OA. Survey findings for: a) healthcare professionals, clinicians, and/or researchers (HCP/Rs) from Survey 1; and b) people with joint damage caused by knee injury and/or osteoarthritis (PJDs) from Survey 2. Six Likert scale options are listed in the key.